Alector, Inc. (ALEC)

NASDAQ: ALEC · Real-Time Price · USD
2.190
-0.330 (-13.10%)
At close: Dec 4, 2024, 4:00 PM
2.160
-0.030 (-1.37%)
After-hours: Dec 4, 2024, 6:20 PM EST
-13.10%
Market Cap 214.47M
Revenue (ttm) 61.51M
Net Income (ttm) -158.41M
Shares Out 97.93M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,433,990
Open 2.350
Previous Close 2.520
Day's Range 2.140 - 2.415
52-Week Range 2.140 - 8.900
Beta 0.51
Analysts Strong Buy
Price Target 14.00 (+539.27%)
Earnings Date Nov 6, 2024

About ALEC

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The compa... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 7, 2019
Employees 244
Stock Exchange NASDAQ
Ticker Symbol ALEC
Full Company Profile

Financial Performance

In 2023, Alector's revenue was $97.06 million, a decrease of -27.36% compared to the previous year's $133.62 million. Losses were -$130.39 million, -2.19% less than in 2022.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ALEC stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 539.27% from the latest price.

Price Target
$14.0
(539.27% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Bank of America Securities has downgraded Alector, Inc.  ALEC, citing the failure of its AL002 program.

5 hours ago - Benzinga

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

On Monday, Alector, Inc.  ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease...

8 days ago - Benzinga

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...

9 days ago - GlobeNewsWire

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has en...

20 days ago - GlobeNewsWire

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024

4 weeks ago - GlobeNewsWire

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will pa...

3 months ago - GlobeNewsWire

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript

Alector, Inc. (NASDAQ:ALEC) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Katie Hogan – Senior Director-Corporate Communications and Investor Relations Arnon Rosenth...

4 months ago - Seeking Alpha

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024

4 months ago - GlobeNewsWire

Alector to Host Mid-Year Earnings Conference Call

Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT

4 months ago - GlobeNewsWire

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baselin...

4 months ago - GlobeNewsWire

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related t...

4 months ago - GlobeNewsWire

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain bar...

6 months ago - GlobeNewsWire

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

10 months ago - Seeking Alpha

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023

10 months ago - GlobeNewsWire

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT

10 months ago - GlobeNewsWire

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally The trial, being conducted in partnership with GSK, is expected to enroll approximately 28...

10 months ago - GlobeNewsWire

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

-Latozinemab is the most advanced progranulin-elevating candidate in development for FTD-GRN and has now become the first investigational medicine to receive a Breakthrough Therapy Designation for the...

10 months ago - GlobeNewsWire

Alector Announces Closing of Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its unde...

11 months ago - GlobeNewsWire

Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation

Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for the treatment of patients with Alzheimer's disease, in Q4 of 2024. IND clearance received to begin a phase 2 study using ...

11 months ago - Seeking Alpha

Alector Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an under...

11 months ago - GlobeNewsWire

Alector Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it intends to offe...

11 months ago - GlobeNewsWire

Alector: Good Data, Huge Cash, No Near Term Catalyst

Alector's stock has traded mostly sideways, down 18% from last year, despite having a promising late-stage CNS pipeline, loads of cash, and two big partnerships. The company has trimmed down its pipel...

11 months ago - Seeking Alpha

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively Leading scientific and clinical experts to p...

1 year ago - GlobeNewsWire

Alector to Participate in the Stifel Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will partici...

1 year ago - GlobeNewsWire

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants

1 year ago - GlobeNewsWire